Novartis struck a licensing deal with China’s Abogen worth up to about $7.8 billion for an experimental RNA therapy and options on additional programs.
Why it matters: this is a useful signal beyond the headline because it affects capital, regulation, technology adoption, public health, Atlanta life or the practical choices people and businesses make.
What to watch next: the next filing, market move, implementation step, scientific measurement or scheduled event will show whether this develops into a durable shift or remains a short-lived headline.